FDA Drops Prostate Cancer Game-Changer

Doctor consulting a patient on a sofa — Photo: Chinnapong / Shutterstock

Men whose prostate cancer came back after surgery or radiation now have a treatment that cut their risk of the disease spreading or killing them by more than half.

Quick Take

A major trial tested adding the drug enzalutamide to standard hormone therapy in men with recurring, non-spread prostate cancer.
The combination lowered the risk of metastasis or death by 58 percent compared to hormone therapy alone.
Five-year survival without the cancer spreading reached 87 percent in the combination group versus 71 percent for standard treatment alone.
The Food and Drug Administration (FDA) approved the combination for this specific group of patients.

A Major Trial Changes The Playbook For Recurring Prostate Cancer

Some men beat prostate cancer once, only to watch their blood tests show it creeping back before it shows up on a scan. This is called biochemical recurrence, and doctors have long debated how aggressively to treat it. A large trial called EMBARK set out to answer that question for men at high risk of their cancer spreading, enrolling 1,068 patients across multiple countries.

Researchers split patients into three groups. One took the drug enzalutamide alongside leuprolide, a standard hormone-blocking shot. Another took leuprolide with a dummy pill. A third took enzalutamide by itself. The trial measured how long patients went without their cancer spreading to other parts of the body, a benchmark doctors call metastasis-free survival.

How The Drug Combination Stacked Up Against Standard Care

The results were striking. Men taking enzalutamide with leuprolide had a risk of cancer spreading or death that was 58 percent lower than men on leuprolide alone, with a hazard ratio of 0.42. That number means the combination group faced less than half the risk seen in the standard-treatment group, a gap wide enough that researchers called it statistically significant without hesitation.

Longer follow-up sharpened the picture even further. At five years, 87 percent of men on the combination had not seen their cancer spread, compared to 71 percent of men on leuprolide alone. That 16-point gap translates into real years many men got to spend without facing a metastatic diagnosis, a milestone that reshapes conversations between patients and their doctors about what comes next.

The FDA Approval And What It Means For Patients

The Food and Drug Administration approved enzalutamide for this patient group in November, allowing doctors to prescribe it either alongside leuprolide or on its own. The approval covers men with what doctors classify as high-risk biochemical recurrence, meaning their rising blood markers suggest a strong chance the cancer will eventually spread without more aggressive treatment. Pfizer and Astellas, which market the drug under the brand name Xtandi, confirmed the expanded approval followed directly from the trial’s data.

Researchers also tracked how the treatment affected daily life, since adding a second drug to hormone therapy raises fair questions about side effects. A companion analysis found the combination did not meaningfully worsen patients’ reported quality of life compared to hormone therapy alone, an important detail for men weighing years of added treatment against the benefit of delaying metastasis.

Why Doctors Are Still Debating How Far To Push Early Treatment

The trial’s main finding is settled, but it sits inside a bigger conversation in prostate cancer care. Doctors increasingly treat rising blood markers earlier and more aggressively, betting that delaying metastasis is worth the added medication. Some specialists note that metastasis-free survival, while meaningful, has not been proven in every setting to line up perfectly with how long patients ultimately live.

That distinction matters for shared decision-making. Guidelines already recommend early systemic therapy for high-risk recurrence because the benefit is clear, while reserving closer observation for lower-risk cases. The EMBARK results give doctors and patients a concrete, FDA-backed option for one of the hardest calls in cancer care: when blood work says the fight isn’t over, even if scans still look clean.

For now, the data gives men facing a recurring diagnosis something they didn’t have before: a tested combination with a clear, measurable edge over the old standard, backed by a federal approval rather than hope alone.